| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
52,420,000 |
| Market
Cap: |
15.99(M) |
| Last
Volume: |
24,690 |
Avg
Vol: |
24,621 |
| 52
Week Range: |
$0.305 - $0.305 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alimera Sciences is a pharmaceutical company that focuses on the commercialization and development of ophthalmic pharmaceuticals. Co. focuses on diseases affecting the retina. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide in the eye, for up to 36 months. ILUVIEN is also used in certain countries in the European Economic Area to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. LUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a needle, which allows for a self-sealing wound.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,980,901 |
1,980,901 |
| Total Buy Value |
$0 |
$0 |
$4,346,042 |
$4,346,042 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
579,000 |
779,919 |
| Total Sell Value |
$0 |
$0 |
$1,962,810 |
$2,276,927 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Myers C. Daniel |
CEO |
• • – |
2018-01-16 |
4 |
AS |
$1.24 |
$32,735 |
D/D |
(26,450) |
154,411 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2017-03-10 |
4 |
S |
$1.39 |
$29,429 |
D/D |
(21,172) |
180,861 |
|
- |
|
| Eiswirth Richard S Jr |
President and CFO |
• – – |
2017-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
70,900 |
105,874 |
|
- |
|
| Ashman Philip |
SVP, EU Managing Director |
• – – |
2017-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
51,000 |
51,000 |
|
- |
|
| Holland David |
SVP of Sales and Marketing |
• – – |
2017-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
51,000 |
160,588 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2017-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
105,800 |
202,033 |
|
- |
|
| Green Kenneth |
SVP & Chief Scientific Officer |
• – – |
2017-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
56,200 |
192,761 |
|
- |
|
| Roberts Calvin W. |
Director |
– • – |
2016-12-12 |
4 |
S |
$1.11 |
$55,500 |
I/I |
(50,000) |
65,820 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-10-31 |
5 |
A |
$1.06 |
$2,608 |
D/D |
2,455 |
98,791 |
|
- |
|
| Holland David |
SVP of Sales and Marketing |
• – – |
2016-10-11 |
4 |
D |
$1.50 |
$37,202 |
D/D |
(24,801) |
109,588 |
|
- |
|
| Holland David |
SVP of Sales and Marketing |
• – – |
2016-10-11 |
4 |
OE |
$1.33 |
$37,201 |
D/D |
27,971 |
134,389 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-10-11 |
4 |
D |
$1.50 |
$73,347 |
D/D |
(48,898) |
96,233 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-10-11 |
4 |
OE |
$1.33 |
$73,346 |
D/D |
55,147 |
145,131 |
|
- |
|
| Green Kenneth |
SVP & Chief Scientific Officer |
• – – |
2016-10-11 |
4 |
OE |
$1.33 |
$58,797 |
D/D |
44,208 |
136,561 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-04-29 |
5 |
A |
$1.89 |
$3,968 |
D/D |
2,103 |
96,336 |
|
- |
|
| Ba Venture Partners Vi, Llc |
10% Owner |
– – • |
2016-04-21 |
4 |
AS |
$2.54 |
$1,239,485 |
D/D |
(478,573) |
3,998,718 |
|
- |
|
| Ba Venture Partners Vi, Llc |
10% Owner |
– – • |
2016-04-20 |
4 |
AS |
$2.02 |
$202 |
D/D |
(100) |
4,477,291 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-03-18 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
94,233 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-02-09 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
95,233 |
|
- |
|
| Myers C. Daniel |
CEO |
• • – |
2016-01-12 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
96,233 |
|
- |
|
| Eiswirth Richard S Jr |
COO and CFO |
• – – |
2015-12-16 |
4 |
AS |
$2.30 |
$35,399 |
D/D |
(15,409) |
34,974 |
|
- |
|
| Eiswirth Richard S Jr |
COO and CFO |
• – – |
2015-12-16 |
4 |
OE |
$1.33 |
$20,494 |
D/D |
15,409 |
50,383 |
|
- |
|
| Green Kenneth |
SVP & Chief Scientific Officer |
• – – |
2015-12-16 |
4 |
OE |
$1.33 |
$58,677 |
D/D |
44,118 |
92,353 |
|
- |
|
| Eiswirth Richard S Jr |
COO and CFO |
• – – |
2015-12-15 |
4 |
AS |
$2.32 |
$72,520 |
D/D |
(31,260) |
34,974 |
|
- |
|
| Eiswirth Richard S Jr |
COO and CFO |
• – – |
2015-12-15 |
4 |
OE |
$1.33 |
$41,576 |
D/D |
31,260 |
66,234 |
|
- |
|
322 Records found
|
|
Page 8 of 13 |
|
|
